CONTEXT: Wnt/β-catenin signaling is related to the pathogenesis of osteoporosis, diabetes, and metabolic diseases. Sclerostin is an inhibitor of Wnt/β-catenin signaling. However, there are few data regarding the relationship between sclerostin levels and metabolic disease. OBJECTIVE: This study aimed to identify the relationship between serum sclerostin levels, body composition markers, and the markers of metabolic disease. DESIGN, SETTING, AND PATIENTS: The present study is a cross-sectional study. We measured serum sclerostin levels in 352 Japanese postmenopausal women and analyzed the relationship of these levels with bone mineral density, abdominal fat mass, and biochemical markers. The mean (sd) age of the subjects was 65.5 (9.3) yr. RESULTS: Serum sclerostin levels were positively correlated with percentages of abdominal and gynoid fat. We also analyzed the association between serum sclerostin levels and biochemical markers related to metabolic diseases. Multivariate analysis revealed that the serum sclerostin levels were significantly correlated with the levels of low-density lipoprotein cholesterol and homocysteine. CONCLUSIONS: The circulating sclerostin levels were associated with fat mass. The circulating sclerostin levels were also correlated with low-density lipoprotein cholesterol and homocysteine.
CONTEXT: Wnt/β-catenin signaling is related to the pathogenesis of osteoporosis, diabetes, and metabolic diseases. Sclerostin is an inhibitor of Wnt/β-catenin signaling. However, there are few data regarding the relationship between sclerostin levels and metabolic disease. OBJECTIVE: This study aimed to identify the relationship between serum sclerostin levels, body composition markers, and the markers of metabolic disease. DESIGN, SETTING, AND PATIENTS: The present study is a cross-sectional study. We measured serum sclerostin levels in 352 Japanese postmenopausal women and analyzed the relationship of these levels with bone mineral density, abdominal fat mass, and biochemical markers. The mean (sd) age of the subjects was 65.5 (9.3) yr. RESULTS: Serum sclerostin levels were positively correlated with percentages of abdominal and gynoid fat. We also analyzed the association between serum sclerostin levels and biochemical markers related to metabolic diseases. Multivariate analysis revealed that the serum sclerostin levels were significantly correlated with the levels of low-density lipoprotein cholesterol and homocysteine. CONCLUSIONS: The circulating sclerostin levels were associated with fat mass. The circulating sclerostin levels were also correlated with low-density lipoprotein cholesterol and homocysteine.
Authors: Yu-Heng Vivian Ma; Ann V Schwartz; Sigurdur Sigurdsson; Trisha F Hue; Thomas F Lang; Tamara B Harris; Clifford J Rosen; Eric Vittinghoff; Gudny Eiriksdottir; Alda M Hauksdottir; Kristin Siggeirsdottir; Gunnar Sigurdsson; Diana Oskarsdottir; Nicola Napoli; Lisa Palermo; Vilmundur Gudnason; Xiaojuan Li Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Soohyun P Kim; Hao Da; Zhu Li; Priyanka Kushwaha; Conor Beil; Lin Mei; Wen-Cheng Xiong; Michael J Wolfgang; Thomas L Clemens; Ryan C Riddle Journal: J Biol Chem Date: 2019-03-06 Impact factor: 5.157
Authors: Rocky Strollo; Andreea Soare; Yeganeh Manon Khazrai; Antonio Di Mauro; Andrea Palermo; Rossella Del Toro; Sara Fallucca; Maria Giovanna Belluomo; Laura Dugo; Mario Pianesi; Paolo Pozzilli; Nicola Napoli Journal: Endocrine Date: 2016-11-25 Impact factor: 3.633
Authors: Keertik Fulzele; Forest Lai; Christopher Dedic; Vaibhav Saini; Yuhei Uda; Chao Shi; Padrig Tuck; Jenna L Aronson; Xiaolong Liu; Jordan M Spatz; Marc N Wein; Paola Divieti Pajevic Journal: J Bone Miner Res Date: 2017-01-05 Impact factor: 6.741